Recent advances in topical delivery of proteins and peptides mediated by soft matter nanocarriers

Witting, Madeleine; Obst, Katja; Frieß, Wolfgang; Hedtrich, Sarah

doi:10.1016/j.biotechadv.2015.01.010

Cited by 55 publications

(27 citation statements)

References 182 publications

(213 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, treatment with the ES-NPs overcame multiple limitations that included rapid elimination from the systemic circulation as a result of renal filtration and susceptibility to enzymatic degradation, the danger of developing an immune response and uptake by the reticuloendothelial system (Witting et al, 2015). The latter allows passage through the smallest capillary vessels and penetration of cells or access to the target site, as well as accumulation in certain solid tumors through the hyper-permeable vasculature that solid tumors exhibit.…”

Section: Discussionmentioning

confidence: 99%

In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma

Xie

Ding

et al. 2017

Drug Delivery

View full text Add to dashboard Cite

The purpose of this study was to prepare endostatin-loaded chitosan nanoparticles (ES-NPs) and evaluate their antitumor effect when combined with paclitaxel (PTX) on Lewis lung carcinoma (LLC) mouse xenografts. ES-NPs were prepared by ionic cross-linking. Characterization of the ES-NPs included size distribution, drug-loading efficiency (DL), and encapsulation efficiency (EE). An in vitro release test was also used to determine the release behavior of the ES-NPs. A subcutaneous LC xenograft model of C57BL/6J mice was established. The mice were randomly divided into six groups: control (0.9% NaCl), ES, PTX, ES-NPs, ES þ PTX, and ES-NPs þ PTX. The tumor volume was dynamically measured for the duration of the experiment. Immunohistochemistry was performed to determine the Ki-67 and microvascular density (MVD) in each group. Serum vascular endothelial growth factor (VEGF) and ES levels were determined by enzyme-linked immunosorbent assay (ELISA). ES-NPs were successfully synthesized and had suitable size distribution and high EE. The NPs were homogenously spherical and exhibited an ideal release profile in vitro. In vivo, tumor growth was significantly inhibited in the ES-NPs þ PTX group. The tumor inhibitory rate was significantly higher in the ES-NPs þ PTX group than in the other groups (p < .05). The results of the immunohistochemical assay and ELISA confirmed that ES-NPs combined with PTX had a strong antiangiogenic effect. ES-NPs can overcome the shortcomings of free ES, such as short retention time in circulation, which enhances the antitumor effect of ES. The antitumor effect was more pronounced when treatment included PTX and ES-loaded NPs.ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 99%

In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma

Xie

Ding

et al. 2017

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Particularly interesting in this context is the use of nanocarriers, which have unique advantages due to their large surface area for adsorption/encapsulation of AMPs and prevention of self-aggregation of the peptides. Furthermore, nanostructured materials enable the design of formulations for local delivery to specific tissues and, by controlling degradation of the carrier, allow time-controlled release of the peptides, in addition to improving metabolic as well as chemical stability of the AMPs (Zhang et al, 2010; Witting et al, 2015; Sandreschi et al, 2016). Importantly, nanocarriers can be prepared from biocompatible and biodegradable materials such as lipids (e.g., phospholipids, triglycerides, cholesterol, and monoolein) and polymers [e.g., cellulose, chitosan, hyaluronic acid, poly lactic-co-glycolic acid (PLGA), and poly lactic acid (PLA)].…”

Section: Innovative Formulation Strategies For Ampsmentioning

confidence: 99%

Antimicrobial Peptides: An Emerging Category of Therapeutic Agents

Mahlapuu

Håkansson

Ringstad

et al. 2016

Front. Cell. Infect. Microbiol.

1,399

1,316

View full text Add to dashboard Cite

Antimicrobial peptides (AMPs), also known as host defense peptides, are short and generally positively charged peptides found in a wide variety of life forms from microorganisms to humans. Most AMPs have the ability to kill microbial pathogens directly, whereas others act indirectly by modulating the host defense systems. Against a background of rapidly increasing resistance development to conventional antibiotics all over the world, efforts to bring AMPs into clinical use are accelerating. Several AMPs are currently being evaluated in clinical trials as novel anti-infectives, but also as new pharmacological agents to modulate the immune response, promote wound healing, and prevent post-surgical adhesions. In this review, we provide an overview of the biological role, classification, and mode of action of AMPs, discuss the opportunities and challenges to develop these peptides for clinical applications, and review the innovative formulation strategies for application of AMPs.

show abstract

“…These physicochemical degradations can lead to loss of therapeutic activity. Another concern with these biomolecules is that they are prone to in vivo biological degradation due to the presence of enzymes (i.e., proteases) in the lungs and assorted clearance in the pulmonary area and the blood [95, 118]. To circumvent these issues, different strategies have been tried and tested for pulmonary applied proteins and peptides.…”

Section: Protein Peptides and Vaccine Deliverymentioning

confidence: 99%

Dry Powder Inhalers: A Focus on Advancements in Novel Drug Delivery Systems

Mehta

2016

Journal of Drug Delivery

View full text Add to dashboard Cite

Administration of drug molecules by inhalation route for treatment of respiratory diseases has the ability to deliver drugs, hormones, nucleic acids, steroids, proteins, and peptides, particularly to the site of action, improving the efficacy of the treatment and consequently lessening adverse effects of the treatment. Numerous inhalation delivery systems have been developed and studied to treat respiratory diseases such as asthma, COPD, and other pulmonary infections. The progress of disciplines such as biomaterials science, nanotechnology, particle engineering, molecular biology, and cell biology permits further improvement of the treatment capability. The present review analyzes modern therapeutic approaches of inhaled drugs with special emphasis on novel drug delivery system for treatment of various respiratory diseases.

show abstract

Recent advances in topical delivery of proteins and peptides mediated by soft matter nanocarriers

Cited by 55 publications

References 182 publications

In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma

In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma

Antimicrobial Peptides: An Emerging Category of Therapeutic Agents

Dry Powder Inhalers: A Focus on Advancements in Novel Drug Delivery Systems

Contact Info

Product

Resources

About